Leqembi pen approved for subcutaneous use in Japan
Eisai has received regulatory approval in Japan for a subcutaneous autoinjector formulation of Leqembi, marketed as Leqembi Pen, for the treatment of early Alzheimer’s disease. The product enables patients or care partners to self-administer two injections totaling 500 mg once weekly, permitting at-
<p>Eisai has received regulatory approval in Japan for a subcutaneous autoinjector formulation of Leqembi, marketed as Leqembi Pen, for the treatment of early Alzheimer’s disease. The product enables patients or care partners to self-administer two injections totaling 500 mg once weekly, permitting at-</p>